Heron Therapeuti
NASDAQCM:HRTX
United States / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
2.20 USD
Day change
-0.06 (-2.65%)
52-week range
1.04 - 3.93
20:59 - Closed
After Hours2.17 -0.03 (-1.36%)
Summary of Heron Therapeuti
Hide this widget
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. ...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| HRTX | Peers | Sector | |
|---|---|---|---|
Market Cap | 335.1 M | 177.9 M | 62.691 M |
Price % of 52 Week High | Premium | 49.1% | 61.8% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -18.8% | -0.7% |
1 Year Price Total Return | -18.8% | -44.6% | -13.2% |
Beta (5 Year) | 1.55 | 1.22 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Heron Therapeuti is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for Heron Therapeuti
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 1 day ago |
| Earnings Power ValueView Updated 2 days ago |
| 10Y Historical FinancialsView Updated 1 day ago |
| 5Y Historical FinancialsView Updated 1 day ago |
| EV / EBIT MultiplesView Updated 2 days ago |
| P/E MultiplesView Updated 2 days ago |
| Price / Book MultiplesView Updated 2 days ago |
| Price / Sales MultiplesView Updated 2 days ago |
| EV / Revenue MultiplesView Updated 2 days ago |
| CAPM WACC ModelView Updated 2 hours ago |
| 10Y DCF EBITDA ExitView Updated 2 days ago |
| 10Y DCF Revenue ExitView Updated 2 days ago |
| 10Y DCF Growth ExitView Updated 2 days ago |
| 5Y DCF EBITDA ExitView Updated 2 days ago |
| 5Y DCF Revenue ExitView Updated 2 days ago |
| 5Y DCF Growth ExitView Updated 2 days ago |
| EV / EBITDA MultiplesView Updated 2 days ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 108 | 127 | 144 | 34 | 41 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 157 | 180 | 178 | 180 | 178 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (149) | (60) | (24) | 2.21 | (12) |
Analyst Notes
April 1, 2025
Hide this widget